Table 3

Logistic regression models for factors associated with CNSD misuse or dependence, estimated using multiple imputations

Independent variablesBivariate modelMultivariate model
OR (95% CI)P valueAdjusted OR (95% CI)P value
Sex
 Male11
 Female1.54 (0.65 to 3.67)0.331.13 (0.39 to 3.21)0.83
Age groups, years
 65–7411
 75–840.90 (0.34 to 2.37)0.831.37 (0.42 to 4.50)0.60
 ≥852.40 (0.75 to 7.65)0.142.30 (0.56 to 9.45)0.25
Education, years
 Basic education (≤10)11
 Secondary education (11–13)0.61 (0.22 to 1.72)0.350.84 (0.23 to 3.03)0.78
 Higher education (≥14)0.86 (0.32 to 2.34)0.771.09 (0.31 to 3.81)0.89
Income (Norwegian krone/year)
 <200 00011
 200 000–349 0000.85 (0.24 to 2.98)0.801.26 (0.26 to 6.26)0.77
 ≥350 0000.49 (0.13 to 1.88)0.300.73 (0.11 to 4.83)0.75
Living alone
 No11
 Yes2.65 (1.14 to 6.18) 0.02 2.06 (0.65 to 6.48)0.22
Polypharmacy (≥5 drugs/day)
 No11
 Yes2.02 (0.39 to 10.55)0.411.88 (0.25 to 14.21)0.54
Concurrent use (of >1 CNSDs)
 No (exclusive use)11
 Yes3.5 (1.44 to 8.54) 0.006 3.99 (1.34 to 11.88) 0.01
Duration of CNSD use (weeks)1.00 (0.99 to 1.00)0.941.00 (0.99 to 1.00)0.33
Anxiety scores (HADS-A)1.08 (0.97 to 1.21)0.141.06 (0.88 to 1.26)0.55
Depression scores (HADS-D)1.05 (0.93 to 1.19)0.410.99 (0.81 to 1.20)0.90
Pain intensity (mm, VAS)1.01 (0.99 to 1.03)0.081.02 (1.01 to 1.04) 0.04
  • Bold, P value <0.05.

  • CNSD, central nervous system depressant drugs; HADS-D/A, Hospital Anxiety and Depression Scale, depression or anxiety subscale; VAS, Visual Analogue Scale.